Moderna has announced a supply agreement with the UK government for an additional 2 million doses of its COVID-19 vaccine candidate, mRNA-1273, to the UK beginning in March 2021.
The UK government has now secured 7 million doses of mRNA-1273. This confirmation comes as the UK continues its efforts to secure access to safe and effective COVID-19 vaccines by establishing a broad portfolio of the most promising vaccines.
“We appreciate the collaboration with the UK government as with many other governments and other key partners around the world,” said Moderna CEO Stéphane Bancel.
“For almost a decade, Moderna has invested in creating and developing a novel platform for designing and manufacturing a new class of mRNA-based vaccines. We are proud of the progress on mRNA-1273 we have made to date including the positive interim analysis from our Phase 3 COVE study.”
Last month, Moderna announced that its vaccine candidate achieved 95% efficiency in the COVE study.
